Literature DB >> 8039150

Present and future projects of the International Breast Cancer Study Group.

A Goldhirsch1, R D Gelber, M Castiglione, K N Price, C M Rudenstam, J Lindtner, J Collins, H J Senn, K W Brunner, E Galligioni.   

Abstract

The International Breast Cancer Study Group (formerly the Ludwig Group) has conducted nine clinical trials since 1978 (see the Appendix for participants and authors). Biologic hypotheses related to the combined use of chemotherapy and endocrine therapy in women with operable breast cancer were tested. Questions of timing of chemotherapy with respect to tumor surgery and late introduction of chemotherapy were also evaluated. Ongoing and future trials continue in this tradition to investigate combinations of available endocrine therapies and cytotoxic agents.

Entities:  

Mesh:

Year:  1994        PMID: 8039150     DOI: 10.1002/1097-0142(19940801)74:3+<1139::aid-cncr2820741524>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.

Authors:  D Ormrod; K Holm; K Goa; C Spencer
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923

Review 2.  Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.

Authors:  A J Coukell; D Faulds
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.

Authors:  M Kaufmann
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.